TCF4 and cutaneous melanoma: FAKi treatment robustly decreased TCF-4 binding to the CCND1 and C-myc promoters and induced a moderate decrease of WNT-11 (Fig. 4F) and S1PR1 promoters (Fig. 4G), in concordance with the TCGA analysis in UM and cutaneous melanoma patients (Fig. 4C).